Press releases

Sequana Medical announces publication of results of Multicentre Randomized Controlled Study for the alfapump®

Sequana Medical AG (“Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology. The study demonstrated that in patients with refractory ascites, the alfapump®: significantly reduces the requirement for LVP compared to standard of...

Sequana Medical Announces Sudden Passing of Founder, President & CEO

The Board of Directors of Sequana Medical AG (“Sequana Medical” or the “Company”) announces with great sadness, the sudden death of its Founder, President and Chief Executive Officer, Noel L. Johnson, Ph. D. Dr. Johnson founded the Company in 2006 and has served as President and Chief Executive Officer since then. Noel originated the idea...

Ian Crosbie joins Sequana Medical as Chief Financial Officer

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, heart disease and certain cancers, announced today the appointment of Ian Crosbie as Chief Financial Officer. “We are delighted to welcome Ian to Sequana Medical....

Former Bayer and Pharmacia Senior Executive Rolf A. Classon joins the Sequana Medical AG Board as Chairman

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems to manage fluid build-up in patients with liver disease, congestive heart failure and certain cancers, announced today that Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, has been appointed Chairman of...

Sequana Medical AG raises CHF 9 million (USD 9.3M) in a Series C Extension

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, announced today that it has raised CHF 9 million ($9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest...

Sequana Medical presented the alfapump® system at this year’s Viszeralmedizin Congress in Leipzig, Germany

Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre. This year, we were proud to organise a...
1 2 3

Subscribe to our Press Releases

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close